Immunomodulatory activity of polysaccharide from Helicteres angustifolia L. on 4T1 tumor-bearing mice - 04/04/18
pages | 8 |
Iconographies | 9 |
Vidéos | 0 |
Autres | 0 |
Graphical abstract |
Highlights |
• | HACP significantly inhibited tumor growth and metastasis in 4T1 tumor-bearing mice. |
• | HACP improved the immune organ indices and CD4+/CD8+ lymphocyte ratios. |
• | HACP regulated the secretion of TNF-α, IL-1β, IFN-γ and IL-6 in the serum of mice. |
• | HACP increased the NK cell activity and splenocyte proliferation. |
Abstract |
To evaluate the in vivo immunomodulatory activity of the crude polysaccharide from Helicteres angustifolia L. (HACP), a 4T1 breast tumor model in BALB/c mice was used in this study. After tumor incubation for 6 days, mice were orally administered with 100, 200, and 300 mg/kg of HACP for 15 days. The results show that HACP administration resulted in a remarkable immunomodulatory effect attributable to the increased spleen and thymus indices, unregulated CD4+/CD8+ ratios in spleen lymphocytes, and the augmentation of IL-1β, IFN-γ, and TNF-α productions in the serum of tumor-bearing mice. The increased immunity resulted in a significant reduction in the tumor weight in 100, 200, and 300 mg/kg of HACP treatment groups, achieving inhibition rates of 34.58 ± 10.20%, 57.80 ± 8.65% and 67.71 ± 5.80%, respectively. In addition, a reduced lung metastasis was also detected in the HACP treatment groups. These findings, for the first time, provide scientific evidence that HACP can improve the immune response in 4T1 tumor-bearing mice, which plays a major role in the antitumor effect. Thus, HACP is prospectively valuable to be developed as new products with immunomodulatory activity and used for the treatment of breast cancer.
Le texte complet de cet article est disponible en PDF.Keywords : Helicteres angustifolia L., Polysaccharide, Immunomodulatory activity, 4T1 tumor-bearing mice
Plan
Vol 101
P. 881-888 - mai 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?